Clinical trials: Rectal Cancer Stage I
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Colorectal Neoplasms
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.
- Trial name
- NCT00631410
- Testing
- sunitinib + mFOLFOX6
- Where
- 3 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study.
- Trial name
- NCT00779311
- Testing
- sorafenib, bevacizumab, mFOLFOX6 regimen
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Accelerated Community Oncology Research Network
Metastatic Colorectal Cancer
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
The Primary Phase I objectives are to determine the recommended phase II dose for the capecitabine and aflibercept doublet combination; and to describe any dose limiting and non-dose limiting toxicities.
- Trial name
- X-TRAP (NCT01661972)
- Testing
- Capecitabine and aflibercept
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- John Strickler, M.D.
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006046
- Testing
- monoclonal antibody hu3S193
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ludwig Institute for Cancer Research
Colorectal Cancer
Azacitidine and CAPOX in Metastatic Colorectal Cancer
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer.
- Trial name
- NCT01193517
- Testing
- Azacitidine, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Colorectal Cancer
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
RATIONALE: Memantine hydrochloride may help people stop smoking by decreasing the symptoms of nicotine withdrawal. PURPOSE: This randomized, pilot phase II trial studies how effective memantine hydrochloride works compared to…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01535040
- Testing
- memantine hydrochloride
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wake Forest University Health Sciences
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Cancer Survivor, Stage I Colorectal Cancer AJCC v8
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
This pilot trial studies how well systems support mapping works in guiding self-management in stage I-III colorectal cancer survivors.
- Conditions
- Cancer Survivor, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8
- Trial name
- NCT03520283
- Testing
- Interview, Questionnaire Administration, System Support Mapping
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Colon Cancer, Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA.
- Trial name
- NCT00159484
- Testing
- EPO906, Celecoxib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Southern California
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment.
- Conditions
- Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Rectal Cancer AJCC v8
- Trial name
- NCT03516942
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- 716 sites in United States
- Volunteers
- 565 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Stage IV Colorectal Cancer
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced colorectal cancer who have failed at least…
- Trial name
- NCT01550510
- Testing
- Ascorbic Acid, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Colorectal Cancer, Precancerous Condition
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT01011478
- Testing
- rosuvastatin
- Where
- 587 sites in United States, Canada
- Volunteers
- 406 people
- Sponsor
- NSABP Foundation Inc
Colorectal Cancer, Colorectal Carcinoma
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Background: Immune-based approaches in colorectal cancer have unfortunately with the notable exception of immune checkpoint inhibition in microsatellite instable (MSI-hi) disease been largely unsuccessful.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer
- Trial name
- NCT03206073
- Testing
- Durvalumab, Tremelimumab, Pexa-Vec
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Panitumumab plus bortezomib for colon cancer
- Trial name
- NCT01504477
- Testing
- Panitumumab and bortezomib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Georgetown University
Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04535401
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe.
- Trial name
- NCT00494221
- Testing
- AZD2171, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 2 sites in Japan
- Volunteers
- 172 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer